PRODUCTS SOLD ON PEPTIDESLABUAE.COM ARE FOR RESEARCH PURPOSES ONLY AND ARE NOT FOR HUMAN OR VETERINARY USE.
PRODUCTS SOLD ON PEPTIDESLABUAE.COM ARE FOR RESEARCH PURPOSES ONLY AND ARE NOT FOR HUMAN OR VETERINARY USE.
Price range: £27.99 through £199.99
Buy Tesamorelin Peptide in UAE – In Stock & Ready to Ship
Tesamorelin is a widely researched peptide known for its role in growth hormone stimulation and visceral adipose tissue studies. Each batch is independently verified at ≥99% purity and comes with a full Certificate of Analysis (COA) and HPLC testing documentation — giving UAE research teams the confidence they need when sourcing peptides for serious work.
For research use only. Not intended for human or veterinary use.
Tesamorelin is a synthetic analogue of Growth Hormone-Releasing Hormone (GHRH) studied in endocrinology and metabolic research for its selective stimulation of pituitary growth hormone secretion and its particularly well-documented influence on visceral adipose tissue reduction — making it one of the most precisely studied GHRH analogues in the growth hormone axis research field. Researchers and institutions across the UAE, Dubai, Abu Dhabi and the wider GCC can source verified, research-grade Tesamorelin with fast international dispatch and full batch documentation included.
✅ ≥99% Purity — HPLC & Mass Spectrometry Verified
✅ Batch-Specific Certificate of Analysis (CoA) Included
✅ Sterile Lyophilised Powder | GMP Manufactured
✅ Fast International Dispatch to UAE & GCC
Tesamorelin is a synthetic peptide analogue of endogenous GHRH (Growth Hormone-Releasing Hormone) consisting of the full 44-amino acid GHRH sequence with a trans-3-hexenoic acid group conjugated to its N-terminus. This modification distinguishes it from both native GHRH and shorter GHRH analogues like Sermorelin — and was specifically designed to improve the peptide’s stability against enzymatic degradation while retaining full GHRH receptor binding activity.
Where Sermorelin uses only the first 29 amino acids of GHRH, Tesamorelin incorporates the complete 44-amino acid sequence — making it the most structurally complete GHRH analogue available as a research tool. This full-length sequence combined with the N-terminal stabilising modification gives Tesamorelin a distinct pharmacological profile compared to truncated GHRH analogues, making it a valuable comparative research tool for laboratories studying GHRH receptor biology and growth hormone axis regulation. Its particularly well-documented pre-clinical and research profile around visceral fat metabolism has made it a notable compound in metabolic endocrinology research, with growing interest from institutions across the UAE and GCC where metabolic health research is an expanding priority.
In controlled laboratory and pre-clinical research settings, Tesamorelin has been studied across a range of endocrinology, metabolic, and body composition research applications:
GHRH Receptor Activation: Tesamorelin acts as a full agonist at GHRH receptors on pituitary somatotroph cells — stimulating growth hormone gene expression and pulsatile GH release through the same receptor mechanism as endogenous GHRH. Studies use Tesamorelin to examine GHRHR binding kinetics, downstream cAMP signalling, and how full-length GHRH receptor engagement compares to truncated analogues.
Growth Hormone Secretion Studies: Research uses Tesamorelin to examine pituitary GH secretion dynamics, exploring how full-length GHRH receptor stimulation influences GH pulse amplitude, frequency, and overall GH axis activity in pre-clinical models.
Visceral Adipose Tissue Research: One of Tesamorelin’s most studied and distinctive research areas is its influence on visceral fat — the deep abdominal fat depot associated with metabolic risk. Studies have examined how GHRH analogue-stimulated GH release affects visceral adipose tissue metabolism, lipolysis, and fat distribution in pre-clinical and research models.
IGF-1 Axis Studies: Research has examined how Tesamorelin-stimulated GH release influences downstream IGF-1 production, exploring how GHRH receptor activation propagates through the GH/IGF-1 axis to produce peripheral metabolic effects in liver and tissue models.
Metabolic Research: Studies have incorporated Tesamorelin into models examining lipid metabolism, insulin sensitivity parameters, and overall metabolic rate — exploring how GHRH-stimulated GH secretion influences the broader metabolic regulatory network.
Body Composition Studies: Pre-clinical research has examined Tesamorelin’s effects on body composition parameters including fat mass distribution, lean mass, and the specific visceral-to-subcutaneous fat ratio — reflecting the compound’s documented influence on adipose tissue compartments.
Comparative GHRH Analogue Research: Tesamorelin’s full 44-amino acid sequence makes it a valuable comparative research tool alongside shorter analogues like Sermorelin — allowing studies to examine how sequence length and N-terminal modification affect GHRH receptor pharmacology and downstream GH axis outcomes.
Cognitive and Neurological Research: Some pre-clinical and early research has examined Tesamorelin in neurological contexts, exploring how GH axis stimulation influences cognitive function markers and brain metabolism parameters — reflecting growth hormone’s documented presence and activity in the central nervous system.
HIV-Associated Lipodystrophy Models: Tesamorelin has been examined in models of metabolic fat redistribution, contributing research insights into how GHRH analogue stimulation of GH secretion affects abnormal fat accumulation and distribution patterns in metabolic research contexts.
All applications listed are research-based only. Tesamorelin is not approved for human therapeutic use as supplied.
Tesamorelin has developed a well-documented and distinctive research profile particularly notable for its visceral fat metabolism findings:
Pre-clinical and research studies examining Tesamorelin have consistently documented its ability to stimulate pulsatile GH secretion through GHRH receptor activation, with research confirming that the full 44-amino acid sequence with N-terminal modification retains complete GHRH receptor binding activity while offering improved resistance to enzymatic degradation compared to native GHRH. Visceral adipose tissue research has produced some of the most distinctive findings in Tesamorelin’s research profile — with studies documenting significant influences on visceral fat parameters in metabolic models, establishing it as one of the most specifically studied GHRH analogues in abdominal fat metabolism research. IGF-1 axis studies have documented Tesamorelin’s downstream influence on IGF-1 production following GHRH receptor activation, confirming the expected propagation of GH axis stimulation through to peripheral tissue IGF-1 effects in pre-clinical models. Metabolic research has examined Tesamorelin’s influence on lipid profiles and insulin sensitivity parameters in pre-clinical settings, with studies exploring the complex interplay between GH axis stimulation and metabolic regulatory systems. Comparative GHRH analogue research has positioned Tesamorelin alongside Sermorelin and CJC-1295, with studies examining how the full-length sequence and N-terminal modification affect pharmacokinetic profile and GHRH receptor engagement duration compared to truncated and modified analogues. Neurological research has explored Tesamorelin in models examining cognitive function and brain metabolism — reflecting growing research interest in the broader effects of GH axis stimulation beyond metabolic and body composition outcomes.
| Feature | Tesamorelin | Sermorelin | CJC-1295 | Native GHRH |
|---|---|---|---|---|
| Sequence Length | Full 44 AA + N-terminal modification | 29 AA (truncated) | 29 AA (modified) | Full 44 AA |
| N-Terminal Modification | Trans-3-hexenoic acid | None | DAC conjugate (some forms) | None |
| Enzymatic Stability | Improved | Moderate | Extended (DAC) | Poor |
| GH Release Pattern | Pulsatile | Pulsatile | Sustained (DAC) | Pulsatile |
| Visceral Fat Research | Extensively studied | Limited | Limited | Limited |
| Research Profile | Well-documented | Well-documented | Well-documented | Reference compound |
| Sequence Completeness | Full length | Truncated | Truncated | Full length |
| Parameter | Specification |
|---|---|
| Full Name | Tesamorelin |
| Type | Full-length GHRH Analogue (44 AA + N-terminal modification) |
| Receptor Target | GHRH Receptor (GHRHR) |
| Purity | ≥99% (HPLC & MS Verified) |
| Form | Sterile Lyophilised Powder |
| Solubility | Sterile water, bacteriostatic water |
| Storage (powder) | -20°C, protect from light |
| Storage (reconstituted) | 2–8°C, use within 2–4 weeks |
Every order of Tesamorelin dispatched to the UAE and GCC includes:
Can I buy Tesamorelin in the UAE?
Yes. We supply research-grade Tesamorelin with international dispatch to the UAE, Dubai, Abu Dhabi, Sharjah and across the GCC. All orders include full batch documentation and are packaged to maintain peptide integrity throughout transit. This compound is supplied strictly for laboratory research use only.
What is the difference between Tesamorelin and Sermorelin?
Both are GHRH analogues that stimulate pituitary GH release through GHRH receptor activation, but they differ significantly in sequence length and structural modification. Sermorelin uses only the first 29 amino acids of GHRH — the minimal sequence required for full receptor activity. Tesamorelin uses the complete 44-amino acid GHRH sequence with an additional N-terminal trans-3-hexenoic acid modification that improves enzymatic stability. This makes Tesamorelin the more structurally complete GHRH analogue, with a distinct research profile particularly around visceral fat metabolism that has not been as extensively documented with Sermorelin.
Why is Tesamorelin specifically associated with visceral fat research?
Tesamorelin’s particularly well-documented research profile around visceral adipose tissue metabolism has made it a distinctive compound in this area. Growth hormone plays a known role in regulating visceral fat through lipolytic signalling in deep abdominal adipose tissue, and Tesamorelin’s GHRH receptor-mediated GH stimulation has been studied specifically in models examining this mechanism. Its visceral fat research profile is more extensively documented than other GHRH analogues, making it the preferred research tool for laboratories specifically studying this metabolic compartment.
What is the significance of the N-terminal modification in Tesamorelin?
The trans-3-hexenoic acid group conjugated to Tesamorelin’s N-terminus was specifically designed to improve the peptide’s resistance to degradation by dipeptidyl peptidase IV (DPP-IV) and other N-terminal peptidases that would rapidly cleave and inactivate native GHRH. This modification allows Tesamorelin to maintain a longer functional half-life than unmodified GHRH while retaining complete GHRH receptor binding activity — making it a more stable and practical research tool for studies requiring consistent GHRH receptor stimulation.
How does Tesamorelin compare to CJC-1295 in research?
Both are GHRH receptor agonists with improved stability compared to native GHRH, but they achieve this through different modifications and produce different GH release profiles. Tesamorelin uses a full 44-amino acid sequence with N-terminal modification, producing pulsatile GH release. CJC-1295 with DAC (Drug Affinity Complex) uses a modified 29-amino acid sequence that binds albumin, producing sustained GH elevation. The choice between them depends on whether the research protocol requires pulsatile or sustained GH axis stimulation.
What purity is required for Tesamorelin endocrinology research?
A minimum of ≥98% is considered research grade, though ≥99% is strongly preferred for sensitive GH secretion assays, GHRH receptor binding studies, and metabolic pre-clinical experiments. All our Tesamorelin is independently verified to ≥99% purity.
How is Tesamorelin reconstituted for laboratory use?
Allow the vial to reach room temperature before opening. Add sterile or bacteriostatic water slowly down the vial wall and swirl gently without shaking. Aliquot immediately if longer-term storage at -80°C is required to preserve peptide integrity and avoid freeze-thaw degradation across multiple experimental uses.
How quickly is Tesamorelin delivered to UAE?
Orders are dispatched promptly via tracked international courier. Delivery to the UAE typically takes 3–5 working days, with packaging designed to maintain peptide stability throughout transit.
Research Disclaimer: Tesamorelin is supplied exclusively for legitimate scientific research purposes conducted within licensed laboratory environments. This product is not intended for human consumption, self-administration, or any therapeutic application. It must be handled by qualified researchers in compliance with applicable UAE regulations and institutional ethics guidelines. Handling should only be performed by qualified laboratory professionals in controlled research settings with appropriate institutional authorisations in place. By purchasing, you confirm that this compound will be used solely for approved in-vitro or pre-clinical research purposes.
Receive News
